Ahmad Khajeh-Mehrizi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ahmad Khajeh-Mehrizi has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Khosro Sadeghniiat-Haghighi
Occupational Sleep Research Center, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
5 shared publications - Masoud Mortezazadeh
Department of Hematology‐Oncology, Cancer Institute, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran
4 shared publications - Ali Montazeri
Population Health Research Group, Health Metrics Research Center, Institute for Health Sciences Research, ACECR, Tehran, Iran
3 shared publications - Mehdi Karimi
Faculty of Medicine Bogomolets National Medical University (NMU) Kyiv Ukraine
3 shared publications Omid Aminian
Tehran University of Medical Sciences
3 shared publications- Kamran Roudini
Department of Internal Medicine, Hematology and Medical Oncology Ward, Cancer research center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (7)
Bleomycin‐Induced Acral Dyshidrosiform Eruption: A Rare Cutaneous Toxicity Mimicking Eczema
Bleomycin toxicity can present as dyshidrotic eczema on acral surfaces, distinct from classic flagellate erythema. This rare eruption is often refractory to corticosteroids but resolves upon drug discontinuation. Early recognition is crucial to avoid unnecessary antimicrobial therapy and to guide timely chemotherapy modification.
- 3 July 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (7)
Open AccessBleomycin‐Induced Acral Dyshidrosiform Eruption: A Rare Cutaneous Toxicity Mimicking Eczema
Bleomycin toxicity can present as dyshidrotic eczema on acral surfaces, distinct from classic flagellate erythema. This rare eruption is often refractory to corticosteroids but resolves upon drug discontinuation. Early recognition is crucial to avoid unnecessary antimicrobial therapy and to guide timely chemotherapy modification.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2026 (1) , 6630563
Efficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis
Purpose: Locally advanced breast cancer (LABC) remains a major therapeutic challenge, with neoadjuvant chemotherapy (NAC) serving as a cornerstone of management. However, direct evidence comparing the efficacy of sequential (AC‐T) and concurrent (TAC) anthracycline–taxane regimens in real‐world Middle Eastern populations remains scarce. This study is aimed at comparing the clinical outcomes of AC‐T and TAC in Iranian women with LABC. Methods: A retrospective cohort study was conducted among 118 patients with Stage III breast cancer treated at Tehran, Iran. Patients received either AC‐T (doxorubicin/cyclophosphamide followed by paclitaxel; n = 70) or TAC (docetaxel/doxorubicin/cyclophosphamide; n = 48). Outcomes included pathological complete response (pCR), overall survival (OS), disease‐free survival (DFS), distant recurrence‐free survival (DRFS), and locoregional recurrence‐free survival (LRFS). Results: Baseline demographic and clinical characteristics were comparable between groups. No significant difference in pCR rates was observed between the groups. The AC‐T regimen showed higher, though nonsignificant, OS at 3, 5, and 10 years (90%, 82%, and 71%, respectively) compared with TAC (83%, 74%, and 57%). Conversely, TAC demonstrated significantly superior 10‐year DRFS (62% vs. 45%, p = 0.019). DFS and LRFS were similar between regimens. Multivariable Cox regression analysis identified ER positivity as the only independent predictor of improved OS (HR = 0.42, 95% CI: 0.29–0.82, p = 0.012) and DFS (HR = 0.36, 95% CI: 0.18–0.73, p = 0.005), whereas the chemotherapy regimen was not independently associated with survival after adjustment for confounders. Conclusion: Both AC‐T and TAC provided effective neoadjuvant control in LABC, with comparable survival outcomes. These findings support individualized regimen selection based on patient profile and tumor biology. Prospective studies are needed to refine region‐specific treatment strategies.
- 1 January 2026
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2026 (1) , 6630563
Open AccessEfficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis
Purpose: Locally advanced breast cancer (LABC) remains a major therapeutic challenge, with neoadjuvant chemotherapy (NAC) serving as a cornerstone of management. However, direct evidence comparing the efficacy of sequential (AC‐T) and concurrent (TAC) anthracycline–taxane regimens in real‐world Middle Eastern populations remains scarce. This study is aimed at comparing the clinical outcomes of AC‐T and TAC in Iranian women with LABC. Methods: A retrospective cohort study was conducted among 118 patients with Stage III breast cancer treated at Tehran, Iran. Patients received either AC‐T (doxorubicin/cyclophosphamide followed by paclitaxel; n = 70) or TAC (docetaxel/doxorubicin/cyclophosphamide; n = 48). Outcomes included pathological complete response (pCR), overall survival (OS), disease‐free survival (DFS), distant recurrence‐free survival (DRFS), and locoregional recurrence‐free survival (LRFS). Results: Baseline demographic and clinical characteristics were comparable between groups. No significant difference in pCR rates was observed between the groups. The AC‐T regimen showed higher, though nonsignificant, OS at 3, 5, and 10 years (90%, 82%, and 71%, respectively) compared with TAC (83%, 74%, and 57%). Conversely, TAC demonstrated significantly superior 10‐year DRFS (62% vs. 45%, p = 0.019). DFS and LRFS were similar between regimens. Multivariable Cox regression analysis identified ER positivity as the only independent predictor of improved OS (HR = 0.42, 95% CI: 0.29–0.82, p = 0.012) and DFS (HR = 0.36, 95% CI: 0.18–0.73, p = 0.005), whereas the chemotherapy regimen was not independently associated with survival after adjustment for confounders. Conclusion: Both AC‐T and TAC provided effective neoadjuvant control in LABC, with comparable survival outcomes. These findings support individualized regimen selection based on patient profile and tumor biology. Prospective studies are needed to refine region‐specific treatment strategies.
- Open Access
- 26 December 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Primary cardiac ewing sarcoma presenting as an infiltrative myocardial mass: a rare case with long-term survival
Ewing sarcoma (ES) is a malignant small round-cell tumor that typically arises in the bones or soft tissue of children and young adults. Although most case
- 26 December 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Open AccessPrimary cardiac ewing sarcoma presenting as an infiltrative myocardial mass: a rare case with long-term survival
Ewing sarcoma (ES) is a malignant small round-cell tumor that typically arises in the bones or soft tissue of children and young adults. Although most case
- Open Access
- 14 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 110-118
Salvage therapy with etoposide and mitoxantrone in patients with refractory acute myeloid leukemia: a retrospective cohort study
Background: Acute myeloid leukemia (AML) presents significant treatment challenges, particularly in refractory or relapsed (R/R) cases. This study evaluates the efficacy and outcomes of the salvage chemotherapy regimen containing etoposide 100 mg/m 2 and mitoxantrone 10 mg/m 2 , both on days 1–5 (EM) in non-M3 AML patients. Methods: In a retrospective cohort study, data from 2011 to 2021 were analyzed for adult non-M3 AML patients in a tertiary referral center. Patients who underwent EM salvage chemotherapy after induction failure were included. Exclusion criteria were patients who died during induction, remission with induction, or ineligible for salvage chemotherapy. Results: Out of 449 non-M3 AML patients, 41 (9.1%) received the EM regimen. Of these, 19 (46.3%) showed no response, 5 (12.2%) achieved partial remission (PR), and 17 (41.5%) attained complete remission (CR). The median overall survival (OS) for all patients was 6 months (95% CI 2.3–9.6), with 12, 24, and 36-month OS rates of 31%, 23%, and 15%, respectively. Patients achieving CR or PR had significantly better outcomes compared to refractory patients. Patients who did not receive hematopoietic stem cell transplantation (HSCT) had a median OS of 7 months, while it was not reached for those who did undergo HSCT. At 36 months, the OS rate was significantly higher in patients who underwent HSCT than in those who did not (71.4% vs. 8.3% P = 0.001). Conclusions: The EM regimen offers a potential pathway to remission for R/R non-M3 AML patients. However, the outcomes are heavily influenced by patient-specific factors and subsequent treatment strategies such as HSCT.
- 14 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 110-118
Open AccessSalvage therapy with etoposide and mitoxantrone in patients with refractory acute myeloid leukemia: a retrospective cohort study
Background: Acute myeloid leukemia (AML) presents significant treatment challenges, particularly in refractory or relapsed (R/R) cases. This study evaluates the efficacy and outcomes of the salvage chemotherapy regimen containing etoposide 100 mg/m 2 and mitoxantrone 10 mg/m 2 , both on days 1–5 (EM) in non-M3 AML patients. Methods: In a retrospective cohort study, data from 2011 to 2021 were analyzed for adult non-M3 AML patients in a tertiary referral center. Patients who underwent EM salvage chemotherapy after induction failure were included. Exclusion criteria were patients who died during induction, remission with induction, or ineligible for salvage chemotherapy. Results: Out of 449 non-M3 AML patients, 41 (9.1%) received the EM regimen. Of these, 19 (46.3%) showed no response, 5 (12.2%) achieved partial remission (PR), and 17 (41.5%) attained complete remission (CR). The median overall survival (OS) for all patients was 6 months (95% CI 2.3–9.6), with 12, 24, and 36-month OS rates of 31%, 23%, and 15%, respectively. Patients achieving CR or PR had significantly better outcomes compared to refractory patients. Patients who did not receive hematopoietic stem cell transplantation (HSCT) had a median OS of 7 months, while it was not reached for those who did undergo HSCT. At 36 months, the OS rate was significantly higher in patients who underwent HSCT than in those who did not (71.4% vs. 8.3% P = 0.001). Conclusions: The EM regimen offers a potential pathway to remission for R/R non-M3 AML patients. However, the outcomes are heavily influenced by patient-specific factors and subsequent treatment strategies such as HSCT.
- Open Access
- 18 March 2025
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 19 (1) , 122
Primary Ewing sarcoma of renal origin with tumor thrombus into inferior vena cava: a case report
Renal-origin Ewing's sarcoma is an extremely rare malignancy often misdiagnosed owing to its nonspecific presentation and similarities to other renal tumors. Accurate diagnosis requires a combination of clinical evaluation and advanced diagnostic techniques. Limited case reports make understanding its clinical course and management challenging. This case report aims to raise awareness of renal-origin Ewing's sarcoma, highlight diagnostic challenges, and discuss effective multidisciplinary management strategies to improve patient outcomes. A 32-year-old Iranian female patient presented with a chief complaint of progressive dyspnea, anorexia, and night sweating in the last 2 weeks before her admission. Computed tomography scan showed a tumoral lesion in the left kidney with thrombosis extending into the left renal vein and inferior vena cava up to the right atrium. The patient underwent open cardiac surgery and a radical nephrectomy. During surgery, the mass protruded from the inferior vena cava into the right atrium; it was ultimately diagnosed as renal-origin Ewing's sarcoma, and EWSR1 rearrangement was confirmed on pathology. This case highlights the importance of a thorough diagnostic approach in patients presenting with a renal mass and the value of a multidisciplinary strategy, combining clinical presentation, imaging, histopathology, immunohistochemistry, and molecular studies to achieve an accurate diagnosis. It underscores the critical need for increased awareness and research into the rare entity of renal-origin Ewing's sarcoma, as clinical and pathological information on this condition is limited. Furthermore, this case emphasizes the necessity of timely diagnosis and tailored management to optimize treatment outcomes and improve survival rates in such rare and challenging presentations. not applicable.
- 18 March 2025
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 19 (1) , 122
Open AccessPrimary Ewing sarcoma of renal origin with tumor thrombus into inferior vena cava: a case report
Renal-origin Ewing's sarcoma is an extremely rare malignancy often misdiagnosed owing to its nonspecific presentation and similarities to other renal tumors. Accurate diagnosis requires a combination of clinical evaluation and advanced diagnostic techniques. Limited case reports make understanding its clinical course and management challenging. This case report aims to raise awareness of renal-origin Ewing's sarcoma, highlight diagnostic challenges, and discuss effective multidisciplinary management strategies to improve patient outcomes. A 32-year-old Iranian female patient presented with a chief complaint of progressive dyspnea, anorexia, and night sweating in the last 2 weeks before her admission. Computed tomography scan showed a tumoral lesion in the left kidney with thrombosis extending into the left renal vein and inferior vena cava up to the right atrium. The patient underwent open cardiac surgery and a radical nephrectomy. During surgery, the mass protruded from the inferior vena cava into the right atrium; it was ultimately diagnosed as renal-origin Ewing's sarcoma, and EWSR1 rearrangement was confirmed on pathology. This case highlights the importance of a thorough diagnostic approach in patients presenting with a renal mass and the value of a multidisciplinary strategy, combining clinical presentation, imaging, histopathology, immunohistochemistry, and molecular studies to achieve an accurate diagnosis. It underscores the critical need for increased awareness and research into the rare entity of renal-origin Ewing's sarcoma, as clinical and pathological information on this condition is limited. Furthermore, this case emphasizes the necessity of timely diagnosis and tailored management to optimize treatment outcomes and improve survival rates in such rare and challenging presentations. not applicable.
- 23 July 2024
- Published by Wolters Kluwer Health in Holistic Nursing Practice
- Vol. 39 (2) , 80-85
Complementary and Alternative Medicine Among Adult Cancer Patients
Although there is limited information on efficacy and safety of complementary and alternative medicine (CAM), they are increasingly used by patients with cancer. We aimed to determine the prevalence and predictors of CAM use among a sample of Iranian cancer patients. In this cross-sectional study, conducted in an outpatient cancer clinic, patients with solid tumors or hematologic malignancies in different stages were asked to complete a questionnaire to measure CAM usage. A total of 131 patients with a median age of 58 years (18–86 years) participated in this study. CAM use was reported by 51.9% (n = 68) of the patients. Female gender and higher education level were significantly associated with the use of CAM (OR = 2.47, P value = .01 and OR = 2.55, P value = .02, respectively). Vitamins and minerals were the most frequently used CAM (n = 37, 54.4%). The main reasons for CAM use were to improve immune system and fight cancer (n = 48, 70.6%) followed by relieve side-effects from conventional cancer treatments (n = 26, 38.2%). Although three (4.4%) patients reported side-effects, most patients (n = 53, 77.9%) were satisfied with their CAM use. Among CAM users, 55 (80.9%) patients had reported their CAM use to physician. The CAM use is highly prevalent among adult cancer patients. Health care providers need to raise their awareness on probable disadvantages or benefits of CAMs and discuss these issues with patients.
- 23 July 2024
- Published by Wolters Kluwer Health in Holistic Nursing Practice
- Vol. 39 (2) , 80-85
Complementary and Alternative Medicine Among Adult Cancer Patients
Although there is limited information on efficacy and safety of complementary and alternative medicine (CAM), they are increasingly used by patients with cancer. We aimed to determine the prevalence and predictors of CAM use among a sample of Iranian cancer patients. In this cross-sectional study, conducted in an outpatient cancer clinic, patients with solid tumors or hematologic malignancies in different stages were asked to complete a questionnaire to measure CAM usage. A total of 131 patients with a median age of 58 years (18–86 years) participated in this study. CAM use was reported by 51.9% (n = 68) of the patients. Female gender and higher education level were significantly associated with the use of CAM (OR = 2.47, P value = .01 and OR = 2.55, P value = .02, respectively). Vitamins and minerals were the most frequently used CAM (n = 37, 54.4%). The main reasons for CAM use were to improve immune system and fight cancer (n = 48, 70.6%) followed by relieve side-effects from conventional cancer treatments (n = 26, 38.2%). Although three (4.4%) patients reported side-effects, most patients (n = 53, 77.9%) were satisfied with their CAM use. Among CAM users, 55 (80.9%) patients had reported their CAM use to physician. The CAM use is highly prevalent among adult cancer patients. Health care providers need to raise their awareness on probable disadvantages or benefits of CAMs and discuss these issues with patients.
- Open Access
- 1 April 2024
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 27 (4) , 206-215
Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran
Background: Neoadjuvant chemotherapy (NCT) has become an increasingly popular approach in management of breast cancer (BC). This study was conducted to evaluate the pathologic response and 36-month recurrence and survival rates of patients with human epidermal growth factor receptor 2 (HER2)-negative BC treated with different NCT regimens. Methods: A total of 163 female patients with HER2-negative BC who received NCT during 2017-2020 were identified from the Clinical Breast Cancer Registry of Iran and entered the study. The prescribed NCT regimens included 4 cycles of doxorubicin plus cyclophosphamide, 4 cycles of doxorubicin plus cyclophosphamide followed by 4 cycles of paclitaxel, 4 cycles of doxorubicin plus cyclophosphamide followed by 4 cycles of docetaxel or 6 cycles of doxorubicin plus cyclophosphamide plus docetaxel (TAC). Results: Thirty-two patients (19.6%) experienced pathologic complete response (pCR). TAC regimen, triple negative-BC and ki67>10% were significantly associated with increased pCR. The recurrence, overall survival (OS) and disease-free survival (DFS) rate at 36 months for all patients were 16.6%, 84.7% and 79.8%, respectively. Type of neoadjuvant regimen as well as age, hormone receptor status, Ki67, grade, clinical stage, type of surgery and pathologic response to chemotherapy did not significantly influence the survival and recurrence; however, TAC results in improved recurrence, OS and DFS rates. Conclusion: This study provides further evidence that NCT is a viable treatment option for patients with HER2-negative BC. The TAC regimen resulted in a significantly higher pCR rate compared to other regimens, but did not result in a significant improvement in recurrence, OS and DFS and rates.
- 1 April 2024
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 27 (4) , 206-215
Open AccessNeoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran
Background: Neoadjuvant chemotherapy (NCT) has become an increasingly popular approach in management of breast cancer (BC). This study was conducted to evaluate the pathologic response and 36-month recurrence and survival rates of patients with human epidermal growth factor receptor 2 (HER2)-negative BC treated with different NCT regimens. Methods: A total of 163 female patients with HER2-negative BC who received NCT during 2017-2020 were identified from the Clinical Breast Cancer Registry of Iran and entered the study. The prescribed NCT regimens included 4 cycles of doxorubicin plus cyclophosphamide, 4 cycles of doxorubicin plus cyclophosphamide followed by 4 cycles of paclitaxel, 4 cycles of doxorubicin plus cyclophosphamide followed by 4 cycles of docetaxel or 6 cycles of doxorubicin plus cyclophosphamide plus docetaxel (TAC). Results: Thirty-two patients (19.6%) experienced pathologic complete response (pCR). TAC regimen, triple negative-BC and ki67>10% were significantly associated with increased pCR. The recurrence, overall survival (OS) and disease-free survival (DFS) rate at 36 months for all patients were 16.6%, 84.7% and 79.8%, respectively. Type of neoadjuvant regimen as well as age, hormone receptor status, Ki67, grade, clinical stage, type of surgery and pathologic response to chemotherapy did not significantly influence the survival and recurrence; however, TAC results in improved recurrence, OS and DFS rates. Conclusion: This study provides further evidence that NCT is a viable treatment option for patients with HER2-negative BC. The TAC regimen resulted in a significantly higher pCR rate compared to other regimens, but did not result in a significant improvement in recurrence, OS and DFS and rates.
- Open Access
- 13 May 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (5) , e0126925
Immunosuppressive Therapy in Patients with Aplastic Anemia: A Single-Center Retrospective Study
Aplastic anemia (AA) is a rare disease in which hematopoietic stem cells are severely diminished resulting in hypocellular bone marrow and pancytopenia. Etiology of AA includes auto immunity, toxins, infection, ionizing radiation, drugs and rare genetic disorders, but in the majority of cases no cause can be identified. In the present study we assessed response rate, survival, relapse and clonal evolution in patients with AA treated with immunosuppressive therapy. Patients with AA who received immunosuppressive therapy between May 1998 and September 2013 were included in this study. Patients with non-severe AA (NSAA) were treated with cyclosporine (CsA) and danazol while patients with severe AA (SAA) as well as patients with NSAA who progressed to SAA after beginning of the treatment, were candidates for receiving antithymocyte globulin in addition to CsA and danazol. Among the 63 studied patients, 29 (46%) had NSAA and 34 (54%) had SAA. Three months after treatment, overall response was 58.6% in NSAA and 12.9% in patients with SAA. Survival of all patients at 5, 10 and 15 years were 73%, 55% and 49%, respectively. Survival rates were significantly higher in patients with NSAA compared to patients with SAA as well as in patients who responded at 6 months compared to non-responders. The relapse risk was 39.7% at 10 years. Relapse occurred in patients who discontinued the therapy more than those who continued taking CsA (p value<0.01). The risk of clonal evolution was 9.9% at 10 years and 22.8% at 15 years after treatment. This long-term retrospective study indicated that immunosuppressive therapy should be recommended to patients with AA. Also, our experience indicated that immunosuppressive therapy should not be discontinued after response to therapy in patients with both NSAA and SAA due to high risk of relapse. Low dose of CsA should be continued indefinitely.
- 13 May 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (5) , e0126925
Open AccessImmunosuppressive Therapy in Patients with Aplastic Anemia: A Single-Center Retrospective Study
Aplastic anemia (AA) is a rare disease in which hematopoietic stem cells are severely diminished resulting in hypocellular bone marrow and pancytopenia. Etiology of AA includes auto immunity, toxins, infection, ionizing radiation, drugs and rare genetic disorders, but in the majority of cases no cause can be identified. In the present study we assessed response rate, survival, relapse and clonal evolution in patients with AA treated with immunosuppressive therapy. Patients with AA who received immunosuppressive therapy between May 1998 and September 2013 were included in this study. Patients with non-severe AA (NSAA) were treated with cyclosporine (CsA) and danazol while patients with severe AA (SAA) as well as patients with NSAA who progressed to SAA after beginning of the treatment, were candidates for receiving antithymocyte globulin in addition to CsA and danazol. Among the 63 studied patients, 29 (46%) had NSAA and 34 (54%) had SAA. Three months after treatment, overall response was 58.6% in NSAA and 12.9% in patients with SAA. Survival of all patients at 5, 10 and 15 years were 73%, 55% and 49%, respectively. Survival rates were significantly higher in patients with NSAA compared to patients with SAA as well as in patients who responded at 6 months compared to non-responders. The relapse risk was 39.7% at 10 years. Relapse occurred in patients who discontinued the therapy more than those who continued taking CsA (p value<0.01). The risk of clonal evolution was 9.9% at 10 years and 22.8% at 15 years after treatment. This long-term retrospective study indicated that immunosuppressive therapy should be recommended to patients with AA. Also, our experience indicated that immunosuppressive therapy should not be discontinued after response to therapy in patients with both NSAA and SAA due to high risk of relapse. Low dose of CsA should be continued indefinitely.
- 18 February 2015
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 35 (S2) , 189-193
Obstructive sleep apnea and excessive daytime sleepiness among patients with type 2 diabetes mellitus: a single-center study from Iran
- 18 February 2015
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 35 (S2) , 189-193
Obstructive sleep apnea and excessive daytime sleepiness among patients with type 2 diabetes mellitus: a single-center study from Iran
- 23 January 2015
- Published by Springer Nature in Quality of Life Research
- Vol. 24 (8) , 2025-2030
The STOP-BANG questionnaire: reliability and validity of the Persian version in sleep clinic population
The snoring, tiredness, observed apnea, blood pressure, body mass index, age, neck circumference, gender (STOP-BANG) is a concise and effective obstructive sleep apnea (OSA) screening tool, part questionnaire (STOP), and part demographic or anthropometric measurements (BANG). The main purpose of this study was to translate this well-liked questionnaire into Persian and assess its reliability and validity in sleep clinic population.
- 23 January 2015
- Published by Springer Nature in Quality of Life Research
- Vol. 24 (8) , 2025-2030
The STOP-BANG questionnaire: reliability and validity of the Persian version in sleep clinic population
The snoring, tiredness, observed apnea, blood pressure, body mass index, age, neck circumference, gender (STOP-BANG) is a concise and effective obstructive sleep apnea (OSA) screening tool, part questionnaire (STOP), and part demographic or anthropometric measurements (BANG). The main purpose of this study was to translate this well-liked questionnaire into Persian and assess its reliability and validity in sleep clinic population.